Takeda gets US nod for Shire takeover
Print Edition
TAKEDA Pharmaceutical Co Ltd yesterday said it has received US approval for its US$62 billion acquisition of London-listed Shire Plc, taking the Japanese firm one step closer to its goal of becoming a global top 10 drugmaker.
Takeda said in a press release it received unconditional clearance from the United States Federal Trade Commission.
The Tokyo-listed firm is still awaiting approval from regulators in China, the European Union and elsewhere, as well from shareholders of both parties.
Chief Executive Christophe Weber has been working to persuade investors about the deal’s cost-saving merits. However, concerns of the financial burden the combined company will carry have weighed heavily on Takeda’s stock price which closed flat yesterday ahead of the announcement. The stock is down 16 percent since the firm first said at the end of March it was eying bidding for Shire.
The drugmaker expects the deal to close in the first half of 2019.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
